Zhejiang Provincial People's Hospital Trials

Zhejiang Provincial People's Hospital	Welcome, Profile Billing Logout

Zhejiang Provincial People's Hospital

Welcome, Profile Billing Logout

0 Trials

4 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yu, Weiming

CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting

470

US, RoW

IBI343

Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed

Locally Advanced Unresectable or Metastatic Solid Tumors

12/25

Xiao, Xiuying

G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Enrolling by invitation

450

RoW

irinotecan, IBI343, paclitaxel

Innovent Biologics (Suzhou) Co. Ltd.

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

12/26

12/27

TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting

168

RoW

TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Gastroesophageal Adenocarcinoma

09/26

09/27